Uniquity Bio Receives $300M Funding for Solrikitug Drug Trials

Uniquity Bio Receives $300M Funding for Solrikitug Drug Trials

Elena Costa
2 min read

Uniquity Bio Receives $300 Million Funding for Solrikitug Trials

Uniquity Bio, a newly established pharmaceutical company based in Pennsylvania, has secured a substantial $300 million investment from Blackstone Life Sciences to advance its monoclonal antibody drug, solrikitug, through Phase II trials for COPD and asthma. The drug, which targets thymic stromal lymphopoietin (TSLP), holds great promise as a life-changing medication for patients with limited treatment options. Uniquity's CEO, Brian Lortie, expresses enthusiasm for the upcoming phase of development, while Blackstone's global head, Nicholas Galakatos, foresees an expanding pipeline for startups in the field of immunology and inflammation.

Key Takeaways

  • Uniquity Bio, a new pharmaceutical company, secures $300 million in funding from Blackstone Life Sciences.
  • Solrikitug, a TSLP-targeting monoclonal antibody, is Uniquity's main asset, licensed from MSD.
  • Solrikitug has been cleared by the FDA for Phase II trials in COPD and asthma.
  • The US markets for COPD and asthma were valued at $18.6 billion and $7.2 billion in 2023, respectively.
  • Solrikitug shows potential for broader applications in different immunology and inflammation programs.


The $300 million funding from Blackstone Life Sciences will greatly bolster Uniquity Bio's phase II trials for solrikitug, potentially revolutionizing treatment options for COPD and asthma. This investment serves as a significant indicator of the growing interest in startups specializing in immunology and inflammation. Companies like MSD, which licensed solrikitug to Uniquity, may experience increased demand for similar assets. Furthermore, the COPD and asthma markets' substantial valuations in 2023 suggest potential expansion. If solrikitug proves effective in the long term, Uniquity Bio's valuation may surge, and Blackstone could yield substantial returns. However, it is vital to recognize the potential risks posed by failures in phase II trials and regulatory setbacks within this investment.

Did You Know?

  • Monoclonal Antibody Drug (solrikitug): Solrikitug, the main asset of Uniquity Bio, is a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a crucial factor in allergic inflammation. TSLP has been associated with various diseases, including COPD and asthma. By focusing on TSLP, solrikitug aims to decrease inflammation and enhance symptoms in affected patients.
  • Thymic Stromal Lymphopoietin (TSLP): TSLP, a cytokine involved in the immune response, is produced by epithelial cells in response to injury, infection, or inflammation. It plays an essential role in the development of allergic inflammation and has been linked to conditions such as COPD and asthma. Solrikitug, Uniquity Bio's monoclonal antibody drug, specifically targets TSLP, making it a promising treatment for these conditions.
  • Phase II Trials & COPD/Asthma Markets: Phase II trials involve testing a new drug's safety, dosage, side effects, and overall effectiveness in a larger group of patients. Solrikitug has been cleared for Phase II trials in COPD and asthma. The substantial valuations of the global COPD and asthma markets in the United States underscore the significant potential market for effective treatments like solrikitug.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings